John Patrick Shannon Jr. - 13 Nov 2025 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Chief Executive Officer and Director, Director
Signature
/s/ Beth Hecht, Attorney-in-Fact
Issuer symbol
XERS
Transactions as of
13 Nov 2025
Net transactions value
-$24,493
Form type
4
Filing time
17 Nov 2025, 17:58:52 UTC
Previous filing
04 Aug 2025
Next filing
06 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Shannon John Patrick Jr Chief Executive Officer and Director, Director C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO /s/ Beth Hecht, Attorney-in-Fact 17 Nov 2025 0001553595

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Options Exercise $13,904 +8,970 +0.34% $1.55 2,666,395 13 Nov 2025 Direct F1
transaction XERS Common Stock Sale $173,402 -23,242 -0.87% $7.46 2,643,153 13 Nov 2025 Direct F1, F2
transaction XERS Common Stock Options Exercise $135,005 +87,100 +3.3% $1.55 2,730,253 14 Nov 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XERS Stock Option (Right to Buy) Options Exercise $0 -8,970 -5.6% $0.000000 151,365 13 Nov 2025 Common Stock 8,970 $1.55 Direct F1, F3
transaction XERS Stock Option (Right to Buy) Options Exercise $0 -87,100 -58% $0.000000 64,265 14 Nov 2025 Common Stock 87,100 $1.55 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.260 to $7.740, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The reporting person received the stock options on February 7, 2017 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. 25% of the options vested on the first anniversary of the vesting commencement date, and the remaining 75% of options vested in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.

Remarks:

Chief Executive Officer and Director